

ASX Announcement | 08 June 2021
Visioneering Technologies (ASX:VTI)

Results of Special Meeting of Stockholders

Atlanta, Georgia, Monday, 07 June 2021 (Tuesday, 08 June 2021 Sydney time): US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering' or 'the Company'), announces the results of its Annual Meeting of Stockholders held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2.

Resolutions were decided by way of a poll, with Resolutions 1.1, 1.2 and 2 being passed. Resolution 3 was a Special Resolution and did not receive the requisite percentage of votes cast to pass, therefore it will not come into effect.

As a result of Resolution 2 passing the charter amendment to effect a reverse stock split will proceed. Stockholders are directed to the ASX announcement of 24 May 2021 which sets out the timetable for this reverse stock split (consolidation). The Company particularly directs stockholders' attention to the last day of trading on a pre-consolidation basis of 17 June 2021.

Ends.

This release was authorized by the CEO, Stephen Snowdy, PhD

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Stephen Snowdy, PhD CEO, Visioneering Technologies, Inc. E: ssnowdy@vtivision.com	Simon Hinsley NWR Communications M: +61 401 809 653 E: simon@nwrcommunications.com.au

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is a health care company making innovative vision care products available to patients and eye care professionals. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from the healthcare industry to provide new solutions for adults and children in need of vision correction.

Headquartered in the United States, Visioneering designs, manufactures, sells and distributes contact lenses around the world. Its flagship product, NaturalVue® Multifocal contact lenses, are prescribed in the large addressable markets of nearsighted children and over-45 adults, and VTI is expanding its portfolio of technologies to address a range of other vision care needs. Since its IPO in 2017, the company has grown operations across the US and recently launched its products in Australia, New Zealand, Singapore, Hong Kong, Canada, and Europe.

Foreign ownership restrictions

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.


Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, plans and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.



Visioneering Technologies, Inc 2021 Annual Meeting

Holder Voting Summary

Shares Issued and Outstanding:	2,363,512,855
Shares Voted:	1,308,514,715
Shares Voted (%):	55.36%

The aggregate number of securities for which proxy votes were received prior to the meeting and for each resolution, were the same as the aggregate number of securities voted on the poll and for each resolution for each poll.

All resolutions were decided by a poll.

Resolution	Vote type	Voted	Voted (%)	Result
Item 1.1 Election of Class I Director - Ms Jean Franchi	For	1,300,551,051	99.39%	Carried
	Withheld	7,963,664	0.61%	
Item 1.2 Election of Class I Director - Mr Andrew Silverberg	For	1,302,642,565	99.55%	Carried
	Withheld	5,872,150	0.45%	
Item 2 Approval of Reverse Stock Split of shares of Class A Common Stock	For	1,293,728,439	98.87%	Carried
	Against	14,676,276	1.12%	
	Abstain	110,000	0.01%	
Item 3 Approval of 10% Placement Facility	For	701,467,131	53.61%	Not Carried
	Against	606,357,088	46.34%	
	Abstain	690,496	0.05%	